FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2164416536> ?p ?o ?g. }

• W2164416536 abstract "Abstract Background The 300IR (index of reactivity) 5‐grass pollen tablet has favorable short‐term and sustained clinical efficacy in patients with grass pollen‐induced allergic rhinoconjunctivitis (ARC). Here, we report maintenance of efficacy and safety over 2 years following treatment discontinuation. Methods Randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter Phase 3 trial in patients aged 18–50 years with ARC. During study years 1–3, patients received a daily sublingual tablet containing either 300IR 5‐grass pollen extract or placebo, according to a discontinuous pre‐ and coseasonal protocol. Study years 4 and 5 were treatment‐free. In response to health authorities’ recommendations, the daily combined score (DCS) was assessed in a post‐hoc analysis as the efficacy endpoint. Components of the DCS were daily rhinoconjunctivitis total symptom score (DRTSS) and daily rescue medication score (DRMS). Results 633 patients with ARC were randomized to placebo (n = 219) or 300IR 5‐grass pollen tablet, beginning 4 months (4 M, n = 207) or 2 months (2 M, n = 207) prior to the estimated start of the grass pollen season and continuing until season's end. During the first post‐treatment year, a statistically significant difference versus placebo in least squares (LS) mean DCS was noted in patients previously receiving active treatment (300IR (2 M) point estimate: −0.16, 95% confidence interval (CI 95% ): [−0.26, −0.06], p = 0.0019; −31.1%; 300IR (4 M) point estimate: −0.13, CI 95% : [−0.23, −0.03], p = 0.0103, −25.3%). During the second post‐treatment year, patients in the 300IR (4 M) group, but not the 300IR (2 M) group, showed a statistically significant difference in LS mean DCS versus placebo (point estimate: −0.11, CI 95% : [−0.21; 0.00], p = 0.0478, −28.1%). This significant efficacy seen during the post‐treatment years in patients previously treated with 5‐grass pollen tablet compared favorably with that during the 3 prior years of active treatment. A statistically significant difference versus placebo was also noted in secondary efficacy measures in both post‐treatment years (except for DRTSS in year 5). In the absence of any active treatment, the safety profile was similar in the active groups versus placebo group during either post‐treatment year. Conclusions In adults with grass pollen‐associated ARC, 5‐grass pollen tablet therapy beginning 4 months before the pollen season and continuing to season's end demonstrated efficacy across all variables during active treatment, and this effect was prolonged for up to 2 years post‐treatment. Trial registration ClinicalTrials.gov identifier: NCT00418379 ." @default.
• W2164416536 created "2016-06-24" @default.
• W2164416536 creator A5039769192 @default.
• W2164416536 creator A5048057602 @default.
• W2164416536 creator A5048797041 @default.
• W2164416536 creator A5068824951 @default.
• W2164416536 creator A5079964062 @default.
• W2164416536 date "2015-01-01" @default.
• W2164416536 modified "2023-10-10" @default.
• W2164416536 title "Prolonged efficacy of the 300IR 5‐grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score" @default.
• W2164416536 cites W1964513777 @default.
• W2164416536 cites W1968932437 @default.
• W2164416536 cites W1973850474 @default.
• W2164416536 cites W1984061355 @default.
• W2164416536 cites W1989956384 @default.
• W2164416536 cites W2019738992 @default.
• W2164416536 cites W2022429437 @default.
• W2164416536 cites W2028280773 @default.
• W2164416536 cites W2028803867 @default.
• W2164416536 cites W2064051611 @default.
• W2164416536 cites W2074474404 @default.
• W2164416536 cites W2078463005 @default.
• W2164416536 cites W2080147488 @default.
• W2164416536 cites W2093792384 @default.
• W2164416536 cites W2121760095 @default.
• W2164416536 cites W2126816655 @default.
• W2164416536 cites W2153804236 @default.
• W2164416536 cites W2156278437 @default.
• W2164416536 cites W2164132449 @default.
• W2164416536 doi "https://doi.org/10.1186/s13601-015-0057-8" @default.
• W2164416536 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4474569" @default.
• W2164416536 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26097680" @default.
• W2164416536 hasPublicationYear "2015" @default.
• W2164416536 type Work @default.
• W2164416536 sameAs 2164416536 @default.
• W2164416536 citedByCount "85" @default.
• W2164416536 countsByYear W21644165362015 @default.
• W2164416536 countsByYear W21644165362016 @default.
• W2164416536 countsByYear W21644165362017 @default.
• W2164416536 countsByYear W21644165362018 @default.
• W2164416536 countsByYear W21644165362019 @default.
• W2164416536 countsByYear W21644165362020 @default.
• W2164416536 countsByYear W21644165362021 @default.
• W2164416536 countsByYear W21644165362022 @default.
• W2164416536 countsByYear W21644165362023 @default.
• W2164416536 crossrefType "journal-article" @default.
• W2164416536 hasAuthorship W2164416536A5039769192 @default.
• W2164416536 hasAuthorship W2164416536A5048057602 @default.
• W2164416536 hasAuthorship W2164416536A5048797041 @default.
• W2164416536 hasAuthorship W2164416536A5068824951 @default.
• W2164416536 hasAuthorship W2164416536A5079964062 @default.
• W2164416536 hasBestOaLocation W21644165361 @default.
• W2164416536 hasConcept C126322002 @default.
• W2164416536 hasConcept C142724271 @default.
• W2164416536 hasConcept C168563851 @default.
• W2164416536 hasConcept C203092338 @default.
• W2164416536 hasConcept C204787440 @default.
• W2164416536 hasConcept C27081682 @default.
• W2164416536 hasConcept C2778715236 @default.
• W2164416536 hasConcept C44249647 @default.
• W2164416536 hasConcept C535046627 @default.
• W2164416536 hasConcept C71924100 @default.
• W2164416536 hasConceptScore W2164416536C126322002 @default.
• W2164416536 hasConceptScore W2164416536C142724271 @default.
• W2164416536 hasConceptScore W2164416536C168563851 @default.
• W2164416536 hasConceptScore W2164416536C203092338 @default.
• W2164416536 hasConceptScore W2164416536C204787440 @default.
• W2164416536 hasConceptScore W2164416536C27081682 @default.
• W2164416536 hasConceptScore W2164416536C2778715236 @default.
• W2164416536 hasConceptScore W2164416536C44249647 @default.
• W2164416536 hasConceptScore W2164416536C535046627 @default.
• W2164416536 hasConceptScore W2164416536C71924100 @default.
• W2164416536 hasIssue "1" @default.
• W2164416536 hasLocation W21644165361 @default.
• W2164416536 hasLocation W21644165362 @default.
• W2164416536 hasLocation W21644165363 @default.
• W2164416536 hasLocation W21644165364 @default.
• W2164416536 hasLocation W21644165365 @default.
• W2164416536 hasOpenAccess W2164416536 @default.
• W2164416536 hasPrimaryLocation W21644165361 @default.
• W2164416536 hasRelatedWork W1859326399 @default.
• W2164416536 hasRelatedWork W2014238892 @default.
• W2164416536 hasRelatedWork W2060361110 @default.
• W2164416536 hasRelatedWork W2360693916 @default.
• W2164416536 hasRelatedWork W2415484199 @default.
• W2164416536 hasRelatedWork W2419505618 @default.
• W2164416536 hasRelatedWork W2580334472 @default.
• W2164416536 hasRelatedWork W3121096891 @default.
• W2164416536 hasRelatedWork W4320086256 @default.
• W2164416536 hasRelatedWork W2464739384 @default.
• W2164416536 hasVolume "5" @default.
• W2164416536 isParatext "false" @default.
• W2164416536 isRetracted "false" @default.
• W2164416536 magId "2164416536" @default.
• W2164416536 workType "article" @default.